Yaso Therapeutics

Yaso Therapeutics is pioneering a nanotechnology-enabled therapeutic platform centered on its patented polymer, Polyphenylene Carboxymethylene (PPCM). The company's lead product candidate, Yaso Gel, is positioned as a non-hormonal, multipurpose prevention technology (MPT) designed for contraception and protection against viral and bacterial pathogens, including drug-resistant strains. Currently in Phase 1 clinical testing for contraception, the platform has demonstrated broad-spectrum in vitro activity against pathogens like HIV, HSV, HPV, SARS-CoV-2, and gonorrhea. Yaso's mission is to address significant unmet needs in global family planning and sexual health by offering a potentially safer, more tolerable, and scalable alternative to existing hormonal contraceptives and prophylactics.

Nanotechnology platform based on Polyphenylene Carboxymethylene (PPCM), a polymer that acts as a physical barrier at the nanoscale to inhibit sperm function for contraception and block viral/bacterial attachment and fusion for anti-infective applications.

In contraception, competes with hormonal methods, copper IUDs, and traditional spermicides. In STI prevention, the landscape includes condoms, pre-exposure prophylaxis (PrEP) for HIV, and a pipeline of other investigational microbicides. Yaso's key differentiator is its non-hormonal, multipurpose, and potentially resistance-proof physical mechanism.